NIH Funding Opportunities
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 5 hours 28 min ago
Science-Based Quality Measurement and Management Development for Opioid Use Disorder Treatment (R61/R33 Clinical Trial Required)
Funding Opportunity RFA-DA-19-005 from the NIH Guide for Grants and Contracts. This FOA solicits applications proposing phased research projects, with transition milestones, to develop and rigorously test the effects of strategies to improve opioid treatment quality measures, both on changes in the measures themselves and on patient outcomes. The overall goal is to advance the field of clinical quality measurement and management in opioid use disorder treatment by generating research better aligning quality measurement with quality improvement.
Notice of Participation and NIMH areas of High Priority Research Topics in PAR-18-596, "Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)"
Notice NOT-MH-18-027 from the NIH Guide for Grants and Contracts
Funding Opportunity PAS-18-698 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks to stimulate HIV/AIDS research within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) that addresses high priority HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR). These priorities are described in NOT-OD-15-137: NIH HIV/AIDS Research Priorities and Guidelines for Determining AIDS Funding.
Notice: Refinement and Testing of Interventions to Sustain ADHD Treatment Effects Across Settings and Developmental Transitions
Notice NOT-MH-18-026 from the NIH Guide for Grants and Contracts
Safe and Effective Devices for Use In Neonatal, Perinatal and Pediatric Care Settings (R43/R44 Clinical Trial Optional)
Funding Opportunity RFA-HD-19-001 from the NIH Guide for Grants and Contracts. A major objective of this funding opportunity announcement (FOA) is to invite SBIR applications to foster collaboration between clinical and bioengineering research communities to develop and test safe, accurate, and effective devices for use in neonatal, perinatal, and pediatric care settings. These can be new devices or improvements on existing devices. The studies may range from concept to developmental phases, with a clear commercialization plan to enable healthcare providers to use them in regular clinical care settings in the population, which is the focus of this FOA.
Notice of National Institute of Neurological Disorders and Stroke (NINDS) IGNITE and CREATE Bio Program Applications Directed at Non-Addictive Pain Therapies
Notice NOT-NS-18-048 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-18-695 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages innovative basic and translational exploratory research into mechanisms of HIV transmission, persistence, pathogenesis and co-morbidities in the oral cavity.
Funding Opportunity PA-18-699 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages innovative basic and translational research into mechanisms of HIV transmission, persistence, pathogenesis and co-morbidities in the oral cavity.
Notice NOT-EY-18-006 from the NIH Guide for Grants and Contracts
Stimulating T4 Implementation Research to Optimize Integration of Proven-effective Interventions for Heart, Lung, and Blood Diseases and Sleep Disorders into Practice (STIMULATE) (R01 Clinical Trial Not Allowed)
Funding Opportunity RFA-HL-19-014 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks late-stage T4 Translation research (T4TR) and implementation studies that will lead to generalizable new knowledge to accelerate the adoption/adaptation, and sustained, high-fidelity use of proven-effective interventions for the prevention, treatment, and control of heart, lung, blood, and sleep disorders or diseases (HLBS conditions). It calls for multi-level strategies for delivery of proven-effective interventions to promote the prevention and management of HLBS conditions. The system-level change(s) being evaluated are to be designed, and findings reported so that others would have a contextually-informed understanding of workflow, workforce, and trade-off considerations. These considerations should reflect cultural and organizational contextual factors and values as they inform feasibility and flexibility of adopting, adaptable and sustainable, proven-effective interventions to address HLBS conditions.
Natural Product, Multi-Site, Clinical Trial, Data Coordinating Center (Collaborative U24 - Clinical Trial Required)
Funding Opportunity PAR-18-697 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) , utilizing the U24 grant funding mechanism, encourages applications for a collaborating Data Coordinating Center (DCC) application that accompanies investigator-initiated, multi-site clinical trials (Phase III and beyond) applications submitted under PAR-18-124 (https://grants.nih.gov/grants/guide/pa-files/PAR-18-124.html). The DCC application must be specific to the collaborating Clinical Coordinating Center (CCC) application. The objective of the DCC application Is lo propose a, comprehensive plan that provides overall project coordination. and administrative, data management and biostatistical support for the proposed clinical trial. Both a DCC application and a corresponding CCC application need to be submitted simultaneously for consideration by NCCIH. Trials for which this FOA applies must be relevant to the research mission of the NCCIH and considered a high priority by the Center. For additional information about the mission, strategic vision, and research priorities of the NCCIH, applicants are encouraged to consult the NCCIH website: (https://www,nocih.nih.gov) . Applicants are encouraged to contact the appropriate Scientific/Research contact for the area of science for which they are planning to develop an application prior lo submitting to this FOA.
Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Natural Products (Collaborative UG3/UH3 Clinical Trial Required)
Funding Opportunity PAR-18-696 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages cooperative agreement applications for investigator-initiated multi-site clinical trials (Phase III and beyond) to study the effects of natural products in NCCIH designated areas of high research priority. Applicants should describe plans for a Clinical Coordinating Center to develop and implement the proposed multi-site clinical trial. The objective of the Clinical Coordinating Center is to provide the design scientific rationale and a comprehensive scientific and operational plan for the clinical trial. The Clinical Coordinating Center is expected to be responsible for project management, participant recruitment and retention strategies, performance milestones, scientific conduct, and dissemination of results. Clinical Coordinating Center applications submitted under this FOA will utilize a two-phase, milestone-driven cooperative agreement (UG3/UH3) funding mechanism. In addition, an accompanying Data Coordinating Center application, submitted under PAR-18-123 (https://grants.nih.gov/grants/guide/pa-files/PAR-18-123.html), proposing a data analysis and data management plan for the clinical project is required. Both a Clinical Coordinating Center application and a corresponding Data Coordinating Center (DCC) application need to be submitted simultaneously for consideration by NCCIH.
Request for Information (RFI): Soliciting Input for the National Institutes of Health (NIH) Strategic Plan for Data Science
Notice NOT-OD-18-134 from the NIH Guide for Grants and Contracts
Advanced Laboratories for Accelerating the Reach and Impact of Treatments for Youth and Adults with Mental Illness (ALACRITY) Research Centers (P50 Clinical Trial Optional)
Funding Opportunity PAR-18-701 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for centers to support transdisciplinary teams of clinical and mental health services researchers, behavioral scientists, social scientists, health information and communications technologists, health systems engineers, decision scientists, and mental health stakeholders (e.g., service users, family members, clinicians, payers) to engage in high-impact studies that will significantly advance clinical practice and generate knowledge that will fuel transformation of mental health care in the United States. Advanced Laboratories for Accelerating the Reach and Impact of Treatments for Youth and Adults with Mental Illness (ALACRITY) Research Centers will support the rapid development, testing, and refinement of novel and integrative approaches for (1) optimizing the effectiveness of therapeutic or preventive interventions for mental disorders within well-defined target populations; (2) organizing and delivering optimized mental health services within real world treatment settings; and (3) continuously improving the quality, impact, and durability of optimized interventions and service delivery within diverse care systems. The ALACRITY Centers program is intended to support research that demonstrates an extraordinary level of synergy across disciplines and has a high potential for increasing the public health impact of existing and emerging mental health interventions and service delivery strategies. The Centers are intended for transdisciplinary projects that could not be achieved using standard research project grant mechanisms. The ALACRITY Centers program is also expected to provide opportunities for graduate students, postdoctoral researchers, and new investigators to participate in transdisciplinary, T2 translational mental health research.
Notice of NLM Participation in PA-18-671 "Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31)"
Notice NOT-LM-18-002 from the NIH Guide for Grants and Contracts
NIH Funding Opportunities
- Collaborative Human Tissue Network (CHTN) (UM1 Clinical Trials Not Allowed)
- Clarification: Assignment Deadlines for Applications Submitted Under the NIH Continuous Submission Policy
- Notice of Clarification for Submission of Materials Related to Communications with FDA for RFA-NS-18-022 "BRAIN Initiative: Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (U44)"
- Notice of Clarification for Submission of Materials Related to Communications with FDA for RFA-NS-18-023 "BRAIN Initiative: Clinical Studies to Advance Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System"
- Notice of Clarification for Submission of Materials Related to Communications with FDA for RFA-NS-18-021 "BRAIN Initiative: Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3)"